

London, 12 November 2009

Doc. Ref.: EMA/HMPC/456845/2008

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

FINAL

COMMUNITY HERBAL MONOGRAPH ON CURCUMA LONGA L., RHIZOMA

DISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	September 2008 November 2008
ADOPTION BY HMPC FOR RELEASE FOR CONSULTATION	6 November 2008
END OF CONSULTATION (DEADLINE FOR COMMENTS)	15 March 2009
REDISCUSSION IN WORKING PARTY ON COMMUNITY MONOGRAPHS AND COMMUNITY LIST (MLWP)	July 2009 September 2009 November 2009
ADOPTION BY HMPC	12 November 2009

KEYWORDS	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Curcuma longa L.; Curcumae longae rhizoma; turmeric root

COMMUNITY HERBAL MONOGRAPH ON CURCUMA LONGA L., RHIZOMA

1. NAME OF THE MEDICINAL PRODUCT

To be specified for the individual finished product.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1

Well-established use	<u>Traditional use</u>
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Curcuma longa L., rhizoma (turmeric root)
	i) Herbal substance Not applicable
	ii) Herbal preparations
	A) Powdered herbal substance
	B) Comminuted herbal substance
	C) Tincture (Ratio of herbal substance to extraction solvent 1:10), extraction solvent ethanol 70% (v/v)
	D) Dry extract (DER 13-25:1), extraction solvent ethanol 96% (v/v)
	E) Dry extract (DER 5.5-6.5:1), extraction solvent ethanol 50% (v/v)
	F) Tincture (Ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 70% (v/v)

3. PHARMACEUTICAL FORM

Well-established use	<u>Traditional use</u>
	Comminuted herbal substance as herbal tea for oral use.
	Herbal preparations in liquid or solid dosage forms for oral use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

© EMEA 2010 2/5

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Well-established use	Traditional herbal medicinal product used to
	increase bile flow for the relief of symptoms of
	indigestion (such as sensation of fullness,
	flatulence, and slow digestion).
	The product is a traditional herbal medicinal
	product for use in the specified indication
	exclusively based upon long-standing use.

4.2. Posology and method of administration

XX 11 1 1' 1 . 1	7D 1'.' 1
Well-established use	<u>Traditional use</u>
	Posology
	Adults and elderly
	A) Powdered herbal substance: 1.5-3.0 g daily;
	B) Comminuted herbal substance for tea preparation: 0.5-1 g, up to 3 times daily as an infusion;
	C) Tincture (1:10): 0.5-1 ml 3 times daily;
	D) Dry extract (13-25:1): 80-160 mg, divided in 2-5 partial doses daily;
	E) Dry extract (5.5-6.5:1): 100-200 mg, 2 times daily;
	F) Tincture (1:5): 10 ml once daily or 5 ml in 60 ml water 3 times daily;
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use')
	Duration of use
	If the symptoms persist longer than 2 weeks, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use.

4.3. Contraindications

Well-established use	<u>Traditional use</u>
	Hypersensitivity to the active substance(s).

© EMEA 2010 3/5

Obstruction of bile duct, cholangitis, liver disease,
gallstones and any other biliary diseases.

4.4. Special warnings and precautions for use

Well-established use	<u>Traditional use</u>
	The use in children and adolescents is not recommended due to lack of adequate data.
	If symptoms worsen during the use of the medicinal product a doctor or a qualified health care practitioner should be consulted.
	For tinctures containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	<u>Traditional use</u>
	None reported.

4.6. Pregnancy and lactation

Well-established use	<u>Traditional use</u>
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during
	pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	<u>Traditional use</u>
	No studies on the effect on the ability to drive and
	use machines have been performed.

4.8. Undesirable effects

Well-established use	<u>Traditional use</u>
	Mild symptoms of dry mouth, flatulence and gastric irritation may occur. The frequency is not known.
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

© EMEA 2010 4/5

4.9. Overdose

Well-established use	<u>Traditional use</u>
	No case of overdose has been reported.

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	<u>Traditional use</u>
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
	Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. PHARMACEUTICAL PARTICULARS

Well-established use	<u>Traditional use</u>
	Not applicable.

7. DATE OF COMPILATION/LAST REVISION

9 November 2009

© EMEA 2010 5/5